Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | RGS12 | O14924 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.50 |
| ▸ | HBB | P68871 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5171611 | 0.83 | PARP1 (0.46) | PARP1MEN1KMT2AUSP2RGS12 | |
| SCHEMBL29485716 | 0.83 | GSK3B (0.52) | PARP1MEN1KMT2AUSP2RGS12 | |
| SCHEMBL112742 | 0.83 | GSK3B (0.52) | PARP1MEN1KMT2AUSP2RGS12 | |
| SCHEMBL30364460 | 0.81 | GSK3B (0.50) | PARP1MEN1KMT2AUSP2RGS12 | |
| Hydrochloric Acid SCHEMBL29864773 | 0.81 | GSK3B (0.50) | PARP1MEN1KMT2AUSP2RGS12 | |
| Hydrochloric Acid SCHEMBL7736928 | 0.81 | GSK3B (0.50) | PARP1MEN1KMT2AUSP2RGS12 | |
| SCHEMBL29025704 | 0.81 | GSK3B (0.50) | PARP1MEN1KMT2AUSP2RGS12 | |
| SCHEMBL2818286 | 0.80 | PARP1 (0.45) | PARP1MEN1KMT2AUSP2RGS12 | |
| Phthalimide SCHEMBL8855990 | 0.79 | GSK3B (0.60) | PARP1MEN1KMT2AUSP2RGS12 | |
| SCHEMBL29372946 | 0.79 | PARP1 (0.53) | PARP1MEN1KMT2AUSP2RGS12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2769715-A2 | Methods for treating autoimmune disorders, and reagents related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8410053-B2 | Methods for treating autoimmune disorders, and reagents related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120232004-A1 | Methods for Treating Autoimmune Disorders, and Reagents Related Thereto | THE BRIGHAM AND WOMEN'S HOSPITAL (US) | 2012-09-13 | — | — | US | disclosed |
| US-20050070459-A1 | treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor | BRIGHAM AND WOMEN"S HOSPITAL (US) | 2005-03-31 | — | — | US | disclosed |
| EP-1487471-A2 | METHODS FOR TREATING AUTOIMMUNE DISORDERS AND REAGENTS RELATED THERETO | Trustees of Tufts College (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003045228-A9 | METHODS FOR TREATING AUTOIMMUNE DISORDERS, AND REAGENTS RELATED THERETO | TUFTS COLLEGE (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2003045228-A2 | METHODS FOR TREATING AUTOIMMUNE DISORDERS, AND REAGENTS RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070459-A1 | treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor | DNPEP, PREP, VIP | PARP1 2015/4885MEN1 2391/4885KMT2A 4683/4885 |
| US-20120232004-A1 | Methods for Treating Autoimmune Disorders, and Reagents Related Thereto | TNF, HLA-DRB1, IAPP | PARP1 3349/4885MEN1 1540/4885KMT2A 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.